C12Y 304/21043
Classical-complement-pathway c3/c5 convertase
Official title: Classical-complement-pathway C3/C5 convertase (3.4.21.43)
C12Y304/21043 (Classical-complement-pathway c3/c5 convertase) appears on 13 US grants and 20 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 20
- Assignees
- 13
- Inventors
- 29
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 2 | 4 |
| 2018 | 1 | 4 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 2 | 2 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating paraproteinemic neuropathy with anti-C2 antibodies18 Aug 2026US 12,708,664 B2argenx BV
- Compositions and methods for the treatment of hepatic diseases and disorders1 Jul 2025US 12,343,361 B2Labyrinth Holdings, LLC
- Control of cellular redox levels8 Apr 2025US 12,268,718 B2
- Compositions and methods for the treatment of hepatic diseases and disorders2 Jan 2024US 11,857,577 B2Labyrinth Holdings, LLC
- Methods and compositions for treatment of Gaucher Disease via modulation of C5a receptor10 May 2022US 11,324,803 B2Children's Hospital Medical Center
- Method for decelerating the decay-dissociation of c3bbb complex9 Jul 2026US 2026/0193372 A1Hoffmann-La Roche Inc.
- Control of Cellular Redox Levels9 Oct 2025US 2025/0312396 A1
- Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies27 Feb 2025US 2025/0066460 A1argenx BV
- Compositions and Methods for the Treatment of Hepatic Diseases and Disorders23 Nov 2023US 2023/0372410 A1Labyrinth Holdings, LLC
- C3/c5 convertase assays1 Sep 2022US 2022/0276261 A1Leibniz-Institut FüR Naturstoff-Forschung Und Infektionsbiologie—Hans-KnöLl-Institut
Most cited
By later US patents
- Streptococcal C5a peptidase vaccine43US 6,355,255 B1Regents of the University of Minnesota · 2002
- Streptococcal C5a peptidase vaccine41US 6,951,653 B2Regents of the University of Minnesota · 2005
- Streptococcal C5a peptidase vaccine6US 7,635,483 B2Regents of the University of Minnesota · 2009
- Compositions and methods for the treatment of hepatic diseases and disorders3US 9,713,630 B2Labyrinth Holdings, LLC · 2017